Nothing Special   »   [go: up one dir, main page]

DK2310359T3 - Organiske forbindelser - Google Patents

Organiske forbindelser

Info

Publication number
DK2310359T3
DK2310359T3 DK09804555.2T DK09804555T DK2310359T3 DK 2310359 T3 DK2310359 T3 DK 2310359T3 DK 09804555 T DK09804555 T DK 09804555T DK 2310359 T3 DK2310359 T3 DK 2310359T3
Authority
DK
Denmark
Prior art keywords
organic compounds
compounds
organic
Prior art date
Application number
DK09804555.2T
Other languages
English (en)
Inventor
Urs Baettig
Anne-Marie D'souza
Peter Hunt
Neil John Press
Simon James Watson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK2310359T3 publication Critical patent/DK2310359T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/52—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
DK09804555.2T 2008-08-04 2009-08-03 Organiske forbindelser DK2310359T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08161765 2008-08-04
US16162709P 2009-03-19 2009-03-19
PCT/EP2009/060061 WO2010015613A1 (en) 2008-08-04 2009-08-03 Organic compounds

Publications (1)

Publication Number Publication Date
DK2310359T3 true DK2310359T3 (da) 2014-04-07

Family

ID=39769571

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09804555.2T DK2310359T3 (da) 2008-08-04 2009-08-03 Organiske forbindelser

Country Status (35)

Country Link
US (5) US7989497B2 (da)
EP (1) EP2310359B1 (da)
JP (1) JP5303645B2 (da)
KR (1) KR101310503B1 (da)
CN (1) CN102171183B (da)
AR (1) AR075071A1 (da)
AU (1) AU2009279123B2 (da)
BR (1) BRPI0916995B8 (da)
CA (1) CA2732932C (da)
CO (1) CO6341623A2 (da)
CU (2) CU24038B1 (da)
DK (1) DK2310359T3 (da)
EA (1) EA020374B1 (da)
EC (1) ECSP11010804A (da)
ES (1) ES2458596T3 (da)
HK (1) HK1155151A1 (da)
HN (1) HN2011000341A (da)
HR (1) HRP20140350T1 (da)
IL (1) IL210836A (da)
JO (1) JO2910B1 (da)
MA (1) MA32536B1 (da)
MX (1) MX2011001378A (da)
MY (1) MY155626A (da)
NZ (1) NZ590708A (da)
PE (1) PE20110205A1 (da)
PL (1) PL2310359T3 (da)
PT (1) PT2310359E (da)
RS (1) RS53264B (da)
SI (1) SI2310359T1 (da)
SV (1) SV2011003831A (da)
TW (1) TWI430791B (da)
UA (1) UA103198C2 (da)
UY (1) UY32025A (da)
WO (1) WO2010015613A1 (da)
ZA (1) ZA201100512B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103198C2 (en) * 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
US8648070B2 (en) * 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
ES2655942T3 (es) 2011-09-02 2018-02-22 Novartis Ag Sal de colina de un compuesto anti-inflamatorio de ciclobutenodiona sustituida
AU2016201916A1 (en) * 2011-09-02 2016-04-21 Novartis Ag Choline salt of an anti-inflammatory substituted cyclobutenedione compound
FR2981935B1 (fr) * 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
CN110420316A (zh) 2013-06-18 2019-11-08 纽约大学 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点
FR3030515B1 (fr) 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
KR20200037857A (ko) * 2017-08-14 2020-04-09 알러간, 인코포레이티드 3,4-이치환된 3-시클로부텐-1,2-디온 및 그의 용도
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
IL275839B2 (en) 2018-01-08 2024-02-01 Chemocentryx Inc Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
NZ773473A (en) 2018-09-21 2023-07-28 Pfizer N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN112759549B (zh) * 2019-11-05 2023-07-28 中国医学科学院药物研究所 3-取代氨基-4-((取代吡啶基)氨基)环丁-3-烯-1,2-二酮类化合物
CN112851635B (zh) * 2019-11-28 2022-09-16 中国医学科学院药物研究所 环状砜类化合物及其制备方法、用途和药物组合物
TW202135858A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 抗ＴＧＦβ抗體和檢查點抑制劑用於治療增殖性疾病之用途
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
IL302553A (en) * 2020-11-05 2023-07-01 Icahn School Med Mount Sinai CXCR1/CXCR2 inhibitors for use in the treatment of myelofibrosis
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354763A (en) * 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US6166050A (en) * 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
JP2002534498A (ja) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤としてのベンゼンスルホンアミド誘導体およびその使用
EP1351933B1 (en) 2001-01-16 2006-11-22 SmithKline Beecham Corporation Il-8 receptor antagonists
BR0208510A (pt) 2001-03-30 2005-04-19 Smithkline Beecham Corporatiio Métodos de sìntese de compostos contendo fenol
US7132445B2 (en) * 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
DK1381590T3 (da) 2001-04-16 2007-10-22 Schering Corp 3,4-disubstituerede cyclobuten-1,2-dioner som CXC-kemokinreceptorligander
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
BR0308739A (pt) 2002-03-18 2005-01-11 Schering Corp Tratamentos em combinação para doenças mediadas por quimiocina
KR100883476B1 (ko) 2004-01-30 2009-02-16 쉐링 코포레이션 Ｃｘｃ-케모킨 수용체 리간드의 결정성 다형체
DE102005001053A1 (de) * 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
JP2008530284A (ja) 2005-02-10 2008-08-07 ワッカー ケミー アクチエンゲゼルシャフト 保護されたイソシアネート基を有する粒子を含有する塗料
US7566718B2 (en) 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
AU2007269572A1 (en) 2006-07-07 2008-01-10 Pharmacopeia, Inc. 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CA2695613A1 (en) * 2006-12-19 2008-06-26 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
US8450348B2 (en) * 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
BRPI0812222A2 (pt) 2007-06-06 2014-12-16 Novartis Ag Compostos ciclobutenodiona substituídos anti-inflamatórios.
US8519168B2 (en) 2007-07-03 2013-08-27 Merck Sharp & Dohme Corp. Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
EP2181102A1 (en) 2007-07-05 2010-05-05 Schering Corporation Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
WO2009073683A2 (en) 2007-12-04 2009-06-11 Schering Corporation Methods of treating copd
PT2444120T (pt) 2007-12-10 2018-01-03 Novartis Ag Análogos da amilorida espirocíclicos como bloqueadores de enac
UA103198C2 (en) * 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010091543A1 (en) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists
ES2655942T3 (es) 2011-09-02 2018-02-22 Novartis Ag Sal de colina de un compuesto anti-inflamatorio de ciclobutenodiona sustituida

Also Published As

Publication number Publication date
HK1155151A1 (en) 2012-05-11
BRPI0916995B8 (pt) 2021-05-25
CN102171183B (zh) 2013-12-25
US8329754B2 (en) 2012-12-11
CU20110142A6 (es) 2012-01-31
PT2310359E (pt) 2014-04-23
SI2310359T1 (sl) 2014-05-30
CU24038B1 (es) 2014-11-27
HRP20140350T1 (hr) 2014-05-23
CO6341623A2 (es) 2011-11-21
US7989497B2 (en) 2011-08-02
CU20110030A7 (es) 2011-12-28
BRPI0916995B1 (pt) 2020-03-10
US8722925B2 (en) 2014-05-13
NZ590708A (en) 2012-07-27
US20130005735A1 (en) 2013-01-03
EA201100299A1 (ru) 2011-10-31
SV2011003831A (es) 2011-07-05
EP2310359B1 (en) 2014-01-15
TWI430791B (zh) 2014-03-21
ZA201100512B (en) 2011-10-26
US20110251206A1 (en) 2011-10-13
ES2458596T3 (es) 2014-05-06
US9115087B2 (en) 2015-08-25
MA32536B1 (fr) 2011-08-01
AU2009279123A1 (en) 2010-02-11
PL2310359T3 (pl) 2014-06-30
AR075071A1 (es) 2011-03-09
UY32025A (es) 2010-03-26
JP5303645B2 (ja) 2013-10-02
UA103198C2 (en) 2013-09-25
EP2310359A1 (en) 2011-04-20
KR101310503B1 (ko) 2013-09-27
CA2732932A1 (en) 2010-02-11
MX2011001378A (es) 2011-03-25
KR20110038168A (ko) 2011-04-13
US20110251205A1 (en) 2011-10-13
CN102171183A (zh) 2011-08-31
HN2011000341A (es) 2013-07-29
BRPI0916995A2 (pt) 2015-11-24
EA020374B1 (ru) 2014-10-30
US20100029670A1 (en) 2010-02-04
ECSP11010804A (es) 2011-03-31
CA2732932C (en) 2017-04-18
MY155626A (en) 2015-11-13
PE20110205A1 (es) 2011-04-07
US8288588B2 (en) 2012-10-16
US20140213594A1 (en) 2014-07-31
JP2011529940A (ja) 2011-12-15
TW201010690A (en) 2010-03-16
RS53264B (en) 2014-08-29
IL210836A0 (en) 2011-04-28
JO2910B1 (en) 2015-09-15
IL210836A (en) 2014-11-30
AU2009279123B2 (en) 2012-08-23
WO2010015613A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
BRPI0922351A2 (pt) compostos orgânicos
BRPI0922700A2 (pt) Compostos orgânicos
BRPI0922348A2 (pt) Compostos orgânicos
BRPI0922809A2 (pt) compostos orgânicos
BRPI0922808A2 (pt) compostos orgânicos
BRPI0922131A2 (pt) Compostos orgânicos
BRPI0913966A2 (pt) compostos orgânicos
BRPI0914698A2 (pt) compostos orgânicos
BRPI0909417A2 (pt) compostos orgânicos
BRPI0915018A2 (pt) compostos orgânicos
DK2310359T3 (da) Organiske forbindelser
BRPI0921826A2 (pt) compostos orgânicos
BRPI0917574A2 (pt) compostos orgânicos
BRPI0907611A2 (pt) Compostos orgânicos
DK2240490T3 (da) Organiske forbindelser
BRPI0817434A2 (pt) Composto orgânicos
BRPI0811562A2 (pt) Compostos orgânicos
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
DK2242759T3 (da) Forbindelser
DK2291384T3 (da) Metalorganiske skeletforbindelser
BRPI0908529A2 (pt) composto orgânicos
BRPI0921533A2 (pt) composto orgânicos
SMT201600045B (it) Composti tetraciclinici c7-fluoro sostituiti
BRPI0821401A2 (pt) Compostos orgânicos